Show simple item record

dc.contributor.authorItsiopoulos, C
dc.contributor.authorMarx, W
dc.contributor.authorMayr, HL
dc.contributor.authorTatucu-Babet, OA
dc.contributor.authorDash, SR
dc.contributor.authorGeorge, ES
dc.contributor.authorTrakman, GL
dc.contributor.authorKelly, JT
dc.contributor.authorThomas, CJ
dc.contributor.authorBrazionis, L
dc.date.accessioned2019-12-02T05:43:13Z
dc.date.available2019-12-02T05:43:13Z
dc.date.issued2018
dc.identifier.issn2352-3859
dc.identifier.doi10.1016/j.jnim.2018.02.002
dc.identifier.urihttp://hdl.handle.net/10072/389447
dc.description.abstractBackground: Type 2 Diabetes Mellitus (T2DM) poses a significant health and financial burden to individuals and healthcare systems. Omega-3 polyunsaturated fatty acids (PUFA) possess numerous properties (e.g. anti-inflammatory, anti-thrombotic, anti-lipidemic) that may be beneficial in the management of T2DM and its complications. Methods: In this narrative review, we discuss the potential mechanisms, clinical evidence-base, and practical considerations regarding the use of omega-3 PUFA supplementation for the management of glycaemic control and common comorbid conditions, including diabetic nephropathy and retinopathy, liver disease, cognition and mental health, and cardiometabolic disease. Results/conclusion: Omega-3 PUFA supplementation is generally well-tolerated and does not appear to be contraindicated for patients on anticoagulant therapy; however, uncertainty persists regarding the purity and stability of commercial omega-3 PUFA products. Despite promising animal studies, the current clinical evidence for the use of omega-3 supplementation for the management of T2DM and associated conditions is both limited and conflicting. Results from existing clinical trials do not support the use of omega-3 PUFA for glycaemic control and there are limited studies in T2DM populations to support the use of omega-3 PUFAs for associated complications of diabetes. Possible contributors to the conflicting evidence base are study design issues, such as inadequate intervention period, sample size, omega 3 supplement dose, variations in the EPA to DHA ratio and clinical heterogeneity among diabetic populations.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherElsevier
dc.publisher.placeNetherlands
dc.relation.ispartofpagefrom42
dc.relation.ispartofpageto51
dc.relation.ispartofjournalJournal of Nutrition and Intermediary Metabolism
dc.relation.ispartofvolume14
dc.subject.fieldofresearchNutrition and Dietetics
dc.subject.fieldofresearchcode1111
dc.titleThe role of omega-3 polyunsaturated fatty acid supplementation in the management of type 2 diabetes mellitus: A narrative review
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationItsiopoulos, C; Marx, W; Mayr, HL; Tatucu-Babet, OA; Dash, SR; George, ES; Trakman, GL; Kelly, JT; Thomas, CJ; Brazionis, L, The role of omega-3 polyunsaturated fatty acid supplementation in the management of type 2 diabetes mellitus: A narrative review, Journal of Nutrition and Intermediary Metabolism, 2018, 14, pp. 42-51
dcterms.licensehttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.date.updated2019-11-29T04:37:02Z
dc.description.versionVersion of Record (VoR)
gro.rights.copyright© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, providing that the work is properly cited.
gro.hasfulltextFull Text
gro.griffith.authorKelly, Jaimon


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record